Evidence map›Paper›PMID 29084755›Full record

ArticleAntimicrobial agents and chemotherapy2018

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.

Peng Xiao, Sanjeev Gumber, Mark A Marzinke, Abhijit A Date, Thuy Hoang, Justin Hanes, Laura M Ensign, Lin Wang, Lisa Rohan, Edward J Fuchs and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Peng Xiao *New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, Louisiana, USA.
Sanjeev Gumber *Division of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Mark A MarzinkeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abhijit A DateCenter for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Thuy HoangCenter for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Justin HanesCenter for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Laura M EnsignCenter for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Lin WangMagee's Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Lisa RohanMagee's Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Edward J FuchsDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Craig HendrixDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Francois VillingerNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, Louisiana, USA Fjv5939@louisiana.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Louisiana at Lafayette · USEmory University · USMagee-Womens Hospital · USUniversity of Pittsburgh · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Tissue pharmacology imaging and modelingU19AI113127 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BUMPUS, NAMANDJE N · 2014 to 2018
$20.7M
NIAID NIH HHS U19 AI113127NIH HHS P51 OD011132
6 · The paper itself

Abstract

Oral preexposure prophylaxis (PrEP) has been approved for prophylaxis of HIV-1 transmission but is associated with high costs and issues of adherence. Protection from anal transmission of HIV using topical microbicides and methods congruent with sexual behavior offers the promise of improved adherence. We compared the pharmacokinetics (PK) and

Indexed as

EnemaAdenineAnimalsAnti-HIV AgentsBiotransformationB-LymphocytesDrug CompoundingKiller Cells, NaturalMacaca mulattaMaleOrganophosphatesOsmolar ConcentrationPre-Exposure ProphylaxisRectumSimian Acquired Immunodeficiency SyndromeT-LymphocytesAdenineAnti-HIV AgentsOrganophosphatestenofovir diphosphateenemahypo-osmolarmonkeytenofovir

Identifiers

PMID29084755
PMCPMC5740373
OpenAlexW2765614584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.